Actively Recruiting
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
Led by Daihong Liu · Updated on 2026-01-07
10
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine the efficacy and safety of the CAR-T cell immunotherapy utilizing polymer-lipid nanoparticles for delivering CD19/CD20 dual-targeting InViVoCAR1920 mRNA, for the first-line consolidation therapy of relapsed/refractory B-cell lymphoma/leukemia.
CONDITIONS
Official Title
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Has voluntarily given informed consent and agrees to comply with study procedures
- Diagnosed with relapsed or refractory B-cell lymphoma or leukemia per WHO 2016 criteria
- Meets specific criteria for B-cell tumors including B-ALL, indolent and aggressive lymphomas
- Aged between 18 and 85 years
- ECOG performance status of 0 to 2
- Expected survival longer than 14 days after consent
- Hemoglobin level at least 60 g/L (transfusion allowed)
- Absolute neutrophil count at least 1,000/µl and platelet count at least 45,000/µl (transfusion allowed)
- Adequate liver, kidney, heart, and lung function as defined by laboratory and clinical measures
- Agreement to use contraception from before enrollment until 6 months post-study
You will not qualify if you...
- Previous CAR or genetically modified T-cell therapy
- History of severe allergic reactions to certain drugs
- Active HIV infection, active hepatitis B infection or uncontrolled systemic infections
- Significant liver or kidney impairment unrelated to lymphoma
- Serious heart diseases or events within 12 months prior to enrollment
- Other severe medical conditions affecting study participation
- Pregnancy or breastfeeding
- Unable or unwilling to comply with study visits and procedures
- Other active or recent cancers except certain skin cancers or carcinoma in situ
- Recent live vaccine within 6 weeks prior to treatment
- Major surgery within 14 days before treatment or planned during study
- Other severe physical, mental illnesses or lab abnormalities increasing study risk or interfering with results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
L
Li-Ping Dou, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here